A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Acronyms SPIRIT
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 02 Apr 2019 Planned End Date changed from 18 Nov 2022 to 22 Nov 2022.
- 02 Apr 2019 Planned primary completion date changed from 18 Nov 2022 to 22 Nov 2022.
- 27 Jun 2018 Planned number of patients changed from 2314 to 1570.